445 related articles for article (PubMed ID: 23393200)
1. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Wang X; Asmann YW; Erickson-Johnson MR; Oliveira JL; Zhang H; Moura RD; Lazar AJ; Lev D; Bill K; Lloyd RV; Yaszemski MJ; Maran A; Oliveira AM
Genes Chromosomes Cancer; 2011 Nov; 50(11):849-58. PubMed ID: 21793095
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Hanes R; Munthe E; Grad I; Han J; Karlsen I; McCormack E; Meza-Zepeda LA; Stratford EW; Myklebost O
Cells; 2019 Feb; 8(2):. PubMed ID: 30795553
[No Abstract] [Full Text] [Related]
4. Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.
Jing W; Lan T; Qiu Y; Peng R; Lu Y; Chen H; Chen M; He X; Chen C; Zhang H
Diagn Pathol; 2021 Oct; 16(1):96. PubMed ID: 34696768
[TBL] [Abstract][Full Text] [Related]
5. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
He X; Pang Z; Zhang X; Lan T; Chen H; Chen M; Yang H; Huang J; Chen Y; Zhang Z; Jing W; Peng R; Zhang H
Am J Surg Pathol; 2018 Sep; 42(9):1143-1155. PubMed ID: 30001240
[TBL] [Abstract][Full Text] [Related]
6. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
Jing W; Lan T; Chen H; Zhang Z; Chen M; Peng R; He X; Zhang H
Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
[TBL] [Abstract][Full Text] [Related]
7. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma.
Chung L; Lau SK; Jiang Z; Loera S; Bedel V; Ji J; Weiss LM; Chu PG
Am J Surg Pathol; 2009 Nov; 33(11):1594-600. PubMed ID: 19574885
[TBL] [Abstract][Full Text] [Related]
8. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.
Hanes R; Grad I; Lorenz S; Stratford EW; Munthe E; Reddy CC; Meza-Zepeda LA; Myklebost O
Oncotarget; 2016 Aug; 7(34):54583-54595. PubMed ID: 27409346
[TBL] [Abstract][Full Text] [Related]
10. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
[TBL] [Abstract][Full Text] [Related]
11. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
[TBL] [Abstract][Full Text] [Related]
12. Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma.
Avallone G; Roccabianca P; Crippa L; Lepri E; Brunetti B; Bernardini C; Forni M; Olandese A; Sarli G
Vet Pathol; 2016 Jul; 53(4):773-80. PubMed ID: 26993784
[TBL] [Abstract][Full Text] [Related]
13. Dedifferentiated liposarcoma with rhabdomyoblastic differentiation.
Shimada S; Ishizawa T; Ishizawa K; Kamada K; Hirose T
Virchows Arch; 2005 Nov; 447(5):835-41. PubMed ID: 16012847
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
15. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.
Cross MJ; Lu L; Magnusson P; Nyqvist D; Holmqvist K; Welsh M; Claesson-Welsh L
Mol Biol Cell; 2002 Aug; 13(8):2881-93. PubMed ID: 12181353
[TBL] [Abstract][Full Text] [Related]
16. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
18. A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2.
Lopez ME; Korc M
J Biol Chem; 2000 May; 275(21):15933-9. PubMed ID: 10748122
[TBL] [Abstract][Full Text] [Related]
19. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
20. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.
Horvai AE; DeVries S; Roy R; O'Donnell RJ; Waldman F
Mod Pathol; 2009 Nov; 22(11):1477-88. PubMed ID: 19734852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
